Latest Fabry Stories
CARMIEL, Israel, Jan. 19, 2011 /PRNewswire/ -- Protalix BioTherapeutics, Inc.
CRANBURY, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will host a live conference call and webcast today, October 29, 2010 at 8:30 a.m.
CAMBRIDGE, Massachusetts, February 24, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. Shire filed a BLA for REPLAGAL in December 2009.
A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure.
CyGene Laboratories Inc. (OTC:CYGE) ("the Company") announced today that it is introducing StrokeScan(TM), a genetic screening test aimed at identifying high risk individuals who have a family history of stroke, cardiovascular or kidney disease.
- A person in a secondary role, specifically the second most important character (after the protagonist).